Patent ID: 9566242
Date: 2017-02-14
CPC Classifications: A61K,A61P

Claim:
1. A method for treating an eye disorder in a patient in need thereof, comprising administering by intravitreal injection into the vitreous chamber of the eye of the patient, an effective amount of a drug delivery system comprising: (i) microparticles comprising a core comprising polylactide or polylactide-co-glycolide; (ii) a coating non-covalently associated with the microparticle core, wherein the coating is formed of amphiphilic molecules comprising a polyethylene glycol hydrophilic region and a hydrophobic region; and (iii) an anti-angiogenic agent encapsulated in or bound to the microparticles, wherein the drug delivery system provides sustained release of the anti-angiogenic agent into the vitreous chamber over a period of time of at least three months; and wherein the vitreous chamber of the eye exhibits at least 10% less inflammation or intraocular pressure compared to the vitreous chamber of an eye treated with the same microparticles not coated with the amphiphilic molecules, for at least about 30 days post-administration.